Shots:
Eli Lilly reported positive topline results from the P-III (ACHIEVE-4) study of Foundayo (orforglipron) vs insulin glargine in ~2,700 pts with type 2 diabetes, and obesity or overweight with elevated CV risk, meeting the 1EP of non-inferiority in MACE-4 events
Foundayo demonstrated a 16% lower risk of MACE-4 and 23% lower risk of MACE-3,…
